Clario Chooses the Box Content Cloud to Power Collaboration for Clinical and Non-Clinical Content
Box (NYSE: BOX) has been selected by Clario to centralize both regulated and unregulated content for its 2,600 employees, enhancing collaboration and data security. Clario, renowned for its clinical trial technology, has completed over 19,000 trials and supported 70% of FDA approvals from 2019 to 2020. Box will streamline Clario's content management and improve workflow efficiency, integrating 12 different systems into one, while maintaining GxP compliance. This partnership signifies Box's growing presence in the life sciences sector.
- Clario deploys Box to its 2,600 employees, enhancing secure collaboration.
- Box will consolidate 12 different content management systems, improving operational efficiencies.
- Clario has a strong track record, having contributed to 870 regulatory approvals.
- None.
Clario delivers leading endpoint technology solutions for decentralized (DCT), hybrid and site-based clinical trials. Over the last 30 years, Clario has completed more than 19,000 clinical trials and has contributed to 870 regulatory approvals. Between 2019 and 2020 alone, the company supported
Since its inception in 1972, the company has grown through the acquisition of cutting-edge biotechnology enterprises. Most recently in 2021, ERT and
“Clario generates rich clinical evidence by fusing scientific expertise and global scale with a groundbreaking endpoint technology platform, minimizing risk in clinical trials around the globe,” said
“Clario is leading the way in clinical trial technology that will transform patients’ lives,” said
Clario is utilizing the Box Content Cloud to:
- Manage and centalize both unregulated and regulated content in the cloud with Box GxP Validation
- Power internal and external collaboration across the global organization
- Protect the company’s most critical data with heightened security
- Leverage Box APIs to enhance and innovate client-facing portals
- Expand on efficiencies through custom automations and workflow
- Power the company’s post-merger consolidation, as the two separate enterprises come together with Box as a common content layer
Box first announced GxP Validation in 2018 as an innovative approach for maintaining GxP compliance in the cloud. With today’s announcement, Clario joins a growing list of leading life science and biotechnology organizations leveraging Box to power new ways of working, including AstraZeneca, Amgen, and Allergan. For more on Box for LifeSciences, visit box.com/industries/life-sciences-biotech.
About Box
Box (NYSE:BOX) is the leading Content Cloud, a single platform that empowers organizations to manage the entire content lifecycle, work securely from anywhere, and integrate across best-of-breed apps. Founded in 2005, Box simplifies work for leading global organizations, including AstraZeneca, JLL, and Nationwide. Box is headquartered in
View source version on businesswire.com: https://www.businesswire.com/news/home/20220616005534/en/
Investor Relations:
+1(650)209-3463
ir@box.com
or
Media Contact:
+44(0)7378162297
press@box.com
Source:
FAQ
What partnership has Box recently announced?
How many employees at Clario will use Box's services?
What has Clario achieved in clinical trials?
What is the significance of Box's GxP Validation?